Colestipol-induced hepatotoxicity

A 65-year-old man with type IIa dyslipidemia who received flavored colestip ol granules 2 scoops/day for 3 months developed asymptomatic hepatotoxicity Several of his liver enzymes were elevated 10 times the upper limit of nor mal. One week after discontinuing colestipol, serum transaminases fell dram atically, with some returning to normal limits. Four weeks after colestipol was discontinued, all liver function tests were normal. Rechallenge was no t attempted. Other potential causes of hepatocellular injury were evaluated . Bile acid-binding resins commonly are administered to treat type IIa dysl ipidemia. Despite extensive use of the resins, significant elevations of tr ansaminase levels are rare. Because the exact mechanism of bile acid resin- induced hepatotoxicity is unknown, high-risk patients may require liver fun ction test monitoring and education on hepatotoxic side effects.